Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress
January 15, 2025 09:52 ET
|
Trethera Corporation
LOS ANGELES, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
January 14, 2025 07:00 ET
|
Kymera Therapeutics, Inc.
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and...
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025 06:30 ET
|
Regeneron Pharmaceuticals, Inc.
Regeneron shares corporate progress and highlights from the Company’s broad and diverse investigational pipeline.
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
January 10, 2025 08:00 ET
|
Barinthus Biotherapeutics
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is...
Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
January 09, 2025 10:00 ET
|
Numab Therapeutics AG
CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and...
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
January 07, 2025 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
GEn1E Lifesciences appoints François Nader, MD as Chair of its Board of Directors
December 11, 2024 07:01 ET
|
GEn1E Lifesciences Inc.
Dr. Nader, current Independent Board Director at Moderna and Senior Advisor at Blackstone Life Sciences, joins GEn1E Lifesciences board as chair.
Bionical Emas sells EMAS Pharma to Kester Capital following strategic review
December 09, 2024 02:00 ET
|
Bionical Emas
Bionical Emas, the Early Access Programs and Clinical Trial Supply business, is selling EMAS Pharma to Kester Capital and an incoming executive team.
Kester Capital backs experienced management team in acquiring EMAS Pharma
December 09, 2024 02:00 ET
|
EMAS Pharma
Kester Capital, alongside a new senior management team, has acquired EMAS Pharma, the clinical development division of Bionical Emas.
Biolojic Design Joins Johnson & Johnson Innovation - JLABS
November 19, 2024 08:00 ET
|
Biolojic Design
Biolojic Design expands U.S. presences by becoming a resident company at Johnson & Johnson JLABS DC